Member Info for amones

jatw, thank you for sharing the information.

as per google, a phase 2 clinical study for surufatinib therapy in patients with net, conducted in california (and houston) (expected completion in september ‘24). results of this study should be useful to understand effectiveness of therapy in non chinese patients. non availability of clinical data in patients of non chinese origin was the primary reason behind failure to get fda approval in 2022.

recent hcm h1 results; revenue generated by elunate (fru*****inib in china) and sulanda ( surufatinib in china) were usd 46 and 25.4 millions, respectively. sulanda revenue has increased by 12% compared to 2023 h1.

finally, can we expect the management at hcm to spend a mere one percent of the $802million positive balance, to buy back shares from the open market. recent short positions number has climbed up to 12.5 million shares :( .

2023, Sulanda China sales USD 50 million.

After 2022 failure to obtain FDA approval, Hutchmed had undertaken Global multi centre studies to study efficacy of Surufatinib in Pancreatic and extrapancreatic neuroendocrinal malignancies. It’s two years since such studies have been taken up. (Prior Clinical studies conducted in China showed positive outcomes which lead to subsequent marketing under Sulanda brand name).

When are the results of multi centre studies going to be published?

Looks like HK stock market is yet to notice Takeda’s H1 Fruzaqla sales figures, announced in the last couple of hours. 0013 is down by 1 HK$. :(

Fruzaqla sales

Thank you jatw for sharing information about sales of Fruzaqla from today’s Takeda H1 financial results.

Hutchmed’s year 2023 results showed Fruzaqla (Takeda) in market sales of USD 15.1 million, bringing a consolidated revenue of USD 7.2 million to Hutchmed.

A quick conversion by google 23 billion Yens equal to 150.8 million USD. Ten times that of whole of year 2023, that too just in first half of the year? Please correct me, if I’m wrong.

So, how much is Hutchmed going to receive from Takeda’s H1 sales of Fruzaqla? Eagerly waiting for a statement from Hutchmed.

Nothing to be surprised about. This was very much expected. Who is interested in the market valuation, any way?

We can only expect the management to decide buy back couple of millions of shares in the open market.

Hopefully, Takeda’s quarterly results, tomorrow, might bring in some cheers.

Several dozens of the same IF, the management considers our wish to buy back few million shares. That will be enough to burn the fingers of the short sellers ;)

If*

https://www.gov.uk/government/news/fru*****inib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer.

i anybody has missed this.

Slight recovery in the share price following today’s RNS. Hopefully, at least this time, there won’t be repetition of ‘ever so common’ decline after few days.

Nice to see investors showing confidence. Unfortunately, we don’t get to know the reasons behind such confidence. Or, it could be a process of filling short positions.

Pencil, I don’t know if the present investor relations are interested in replying to queries from privates investors. This has been my personal experience.

We can only hope the management can start thinking about rewarding the investors (and HCM employees), at least, from now onwards. Few months ago, jatw had quoted a small dividend of (?10p) was very much feasible.

What is the future for this stock? Will the investors who invested at the time of HK listing, get back their money? This company has periodically been announcing positive data and successes in clinical trials of in house developed drug candidates, licenses to sell and profitable marketing arrangements with other major players. The question bothering is why all these achievements are not mirrored in its stock market valuation?

Few years ago, a major ‘corner stone’ investor had one of their influential personal appointed at HCM board (forgotten under what capacity). We used to read messages that it would improve shareholders’ interests! Is that person still active in the bod? This management doesn’t seem to show any concern towards its shareholders. Why is the management not buying few million of its shares from the open markets and support the sp from falling? Recent financial figures show they have been making good earnings. There’s no news about any dividends paid to the shareholders in the near future. At the least, portion of the money in the company’s account can be spent to support the languishing sp. If the ‘influential person’ still actively engaged with the bod, he or she should be asking a question or two. If not, it can only help to nurture a sense of speculation.

how far away is japanese pmda approval decision day for fru*****inib? found this online. not able to read the full article as i don’t have subscription. however, the first line is promising.

https://pj.jiho.jp/article/251453

the market makers shaking the tree? or, something else?

Following a normal trading pattern during the first hour, 0013 dropped 5%. By lunchtime, 14.7 million shares traded. Looks like significant offloading. Curiously there is no fresh news released today either.

Being a smaller company, is there a ‘disadvantage’ of being vulnerable for a buyout ? (;

It would be nice to see announcement of first ever dividend, next week.

thanks jatw for posting.

perhaps did not get the appropriate response as it was friday afternoon. surer, it will be bigger news in the morning, at hk. expecting an uplift tomorrow as it has been said that european market is much bigger than us for fru*****inib. has takeda quoted expected european sales figures?

waiting to see monday opening price in hk.

Even if Cavendish’s “investment research“ is only half correct, why is the market valuation so poor? It would have been interesting if cavendish had provided, for an example, market valuation of another pharma company with similar pipeline and products in the market bringing nice profits.

What are the reasons for the share price to come down from £3.50 (achieved following Takeda results)? When will this company get the correct recognition it deserves in the stock markets?

following takeda results , hutchmed could have informed shareholders about first quarter payment from takeda, arising from fru*****inib global sales. also, anticipated annual earnings from fru*****inib global (specifically in usa) sales would have helped to maintain a stable share price. even now, it is not too late for releasing news about earnings as well as an update about approvals from european and japanese authorities.

Moving to FTSE 250 list was discussed in the past.

2 -3 years ago, I had emailed the company asking if the management was considering such a move. I had quoted the advantages often discussed on this forum, such as getting wider publicity and attracting investments from major funds. Mr Hogg, then CEO, had replied that the company was aware of the potential of such a move, but they had other priorities. Is it correct, moving to the main market would include expensive administrative affair?

ss aka hcms, agree with you. it’s been good two to three consecutive weeks for hcm. hopefully, we are approaching towards the brighter end of the tunnel. last two years had been rough ride for the long term shareholders. over the other side of world, experience of investors who joined during hkse listing of “lucky” 0013 has been not so pleasant either. in spite of the recent progress, friday’s closing sp is well behind the listing price (?hkse40).

i was reading recent posts on adv.n from 1jat (?a.k.a jatw). the company is cash rich and a dividend of 10p per share/ hk$ 1 is possible, provided the management wishes to express their gratitude towards the shareholders. however, the company has passed a resolution in its agm giving right to the directors to buy back the shares. which is better, buy back scheme or a first ever dividend?

takeda’s financial figures (fru*****inib sales) are very encouraging. is hcm obliged to release a statement quoting the actual payment /profit resulting from fruq… golbal sales ? that should help shareholders to understand the actual profit from that source.

thanks to jatw for the informative posts.